T
Tetsuya Mitsudomi
Researcher at Kindai University
Publications - 583
Citations - 51959
Tetsuya Mitsudomi is an academic researcher from Kindai University. The author has contributed to research in topics: Lung cancer & Epidermal growth factor receptor. The author has an hindex of 97, co-authored 541 publications receiving 46183 citations. Previous affiliations of Tetsuya Mitsudomi include University of Occupational and Environmental Health Japan & Gunma University.
Papers
More filters
Journal ArticleDOI
Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Yoshimasa Shiraishi,Junji Kishimoto,Kentaro Tanaka,Shunichi Sugawara,Haruko Daga,Katsuya Hirano,Koichi Azuma,Osamu Hataji,Hidetoshi Hayashi,Motoko Tachihara,Tetsuya Mitsudomi,Takashi Seto,Kazuhiko Nakagawa,Nobuyuki Yamamoto,Isamu Okamoto +14 more
TL;DR: A phase 3 study to investigate the effect of adding bevacizumab to an ICI and platinum/pemetrexed combination therapy and if the primary objective is achieved, this study will provide a new standard treatment for cytotoxic chemotherapy-naive patients with advanced nonsquamous NSCLC.
Journal ArticleDOI
Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.
Kazuhiko Shien,Tsuyoshi Ueno,Kazunori Tsukuda,Junichi Soh,Kenichi Suda,Takafumi Kubo,Masashi Furukawa,Takayuki Muraoka,Yuho Maki,Norimitsu Tanaka,Hiromasa Yamamoto,Katsuyuki Kiura,Tetsuya Mitsudomi,Shinichi Toyooka,Shinichiro Miyoshi +14 more
TL;DR: Analysis of the results indicated that EGFR can be a therapeutic target in NSCLCs with EGFR activation and is not appropriate for tumors in which EGFR is not activated, even if EG FR is expressed.
Journal ArticleDOI
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
Toshio Fujino,Kenichi Suda,Takamasa Koga,Akira Hamada,Shuta Ohara,Masato Chiba,Masaki Shimoji,Toshiki Takemoto,Junichi Soh,Tetsuya Mitsudomi +9 more
TL;DR: In this article , the authors explored agents that are active against both D1228X and Y1230X MET to propose an ideal sequential treatment after capmatinib/tepotinib treatment failure in NSCLC patients with METex14.
Journal ArticleDOI
Gefitinib combined survival analysis of the mutation positives from the prospective phase II trials (I-CAMP)
Satoshi Morita,Tomonori Hirashima,Koichi Hagiwara,Toyoaki Hida,Noriaki Sunaga,Kenji Sugio,Akira Inoue,Koichi Yamazaki,Tetsuya Mitsudomi,Toshihiro Nukiwa +9 more
TL;DR: A combined analysis of seven prospective trials conducted in Japan examining the efficacy and safety of gefitinib monotherapy for advanced NSCLC pts with EGFR mutations and prognostic factors for OS and PFS using a Cox regression model is carried out.
Journal ArticleDOI
Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors.
Denis Soulières,Juergen Wolf,Frances A. Shepherd,Federico Cappuzzo,P. A. Bunn,Roy S. Herbst,Fred R. Hirsch,Keith M. Kerr,Tetsuya Mitsudomi,Ming-Sound Tsao,C. Yang,Frank C. Richardson,Barbara Klughammer,Bret Wacker,D. Sternberg,Angela M. Davies +15 more
TL;DR: Based on a meta-analysis using two phase III, placebo-controlled trials of erlotinib, EGFR mutation testing, while of value in the first-line setting, should not be used to positively or negatively select patients for maintenance/second-line erlot inib.